- Home
- GGN vs PHAR Comparison
GGN vs PHAR Comparison
Compare GGN & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGN
- PHAR
- Stock Information
- Founded
- GGN 2005
- PHAR 1988
- Country
- GGN United States
- PHAR Netherlands
- Employees
- GGN N/A
- PHAR N/A
- Industry
- GGN Finance/Investors Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- GGN Finance
- PHAR Health Care
- Exchange
- GGN Nasdaq
- PHAR Nasdaq
- Market Cap
- GGN 663.2M
- PHAR 627.5M
- IPO Year
- GGN N/A
- PHAR N/A
- Fundamental
- Price
- GGN $3.85
- PHAR $9.10
- Analyst Decision
- GGN
- PHAR Strong Buy
- Analyst Count
- GGN 0
- PHAR 3
- Target Price
- GGN N/A
- PHAR $27.00
- AVG Volume (30 Days)
- GGN 397.4K
- PHAR 7.3K
- Earning Date
- GGN 01-01-0001
- PHAR 10-24-2024
- Dividend Yield
- GGN 10.26%
- PHAR N/A
- EPS Growth
- GGN N/A
- PHAR N/A
- EPS
- GGN N/A
- PHAR N/A
- Revenue
- GGN N/A
- PHAR $285,745,000.00
- Revenue This Year
- GGN N/A
- PHAR $20.89
- Revenue Next Year
- GGN N/A
- PHAR $11.15
- P/E Ratio
- GGN N/A
- PHAR N/A
- Revenue Growth
- GGN N/A
- PHAR 30.64
- 52 Week Low
- GGN $3.51
- PHAR $6.65
- 52 Week High
- GGN $3.91
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- GGN 24.79
- PHAR 61.21
- Support Level
- GGN $4.10
- PHAR $8.24
- Resistance Level
- GGN $4.11
- PHAR $9.59
- Average True Range (ATR)
- GGN 0.06
- PHAR 0.35
- MACD
- GGN -0.03
- PHAR 0.10
- Stochastic Oscillator
- GGN 9.18
- PHAR 76.89
About GGN GAMCO Global Gold Natural Resources & Income Trust
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option strategy of writing (selling) covered call options on equity securities in its portfolio.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.